William G. Wierda, MD, PhD

Articles

Dr Wierda on the Genomic Evolution of Pirtobrutinib in Pretreated CLL

January 30th 2024

William G. Wierda, MD, PhD, discusses the genomic evolution of pirtobrutinib in pretreated chronic lymphocytic leukemia.

Optimizing the Treatment of CLL With Novel Therapies

March 14th 2022

Oncologist-hematologists discuss the outlook for treating patients with chronic lymphocytic leukemia with newer novel therapies.

CAR T-Cell Therapies in CLL

March 14th 2022

Take-home messages from ASH 2021 regarding the role of CAR T-cell therapies in chronic lymphocytic leukemia.

PI3K Inhibitors for CLL

March 7th 2022

A comparison of 3 PI3K inhibitors—idelalisib, duvelisib, and umbralisib—as treatment for chronic lymphocytic leukemia.

Noncovalent BTK Inhibitors in CLL

March 7th 2022

Recommendations for applying information from clinical trials presented at oncology and hematology conferences in 2021 into routine clinical practice when managing patients with chronic lymphocytic leukemia.

Novel Therapies for CLL in the Context of COVID-19

February 28th 2022

What to know in terms of COVID-19 vaccine responses in patients with chronic lymphocytic leukemia on novel targeted therapies.

Novel Therapies for CLL: Sequencing Strategies

February 28th 2022

Factors that impact decisions for frontline and subsequent lines of therapy for patients with chronic lymphocytic leukemia.

Treating CLL With Anti-CD20 Antibody Regimens

February 21st 2022

Recommendations for combining an anti-CD20 antibody with a Bruton tyrosine kinase inhibitor or venetoclax in doublet or triplet regimens for the treatment for chronic lymphocytic leukemia (CLL).

Chemotherapy-Free Regimens as Frontline Therapy in CLL

February 21st 2022

Key takeaways of the CLL13 (GAIA) clinical trial based on highlights presented at ASH 2021.

Fixed-Duration Therapy in Relapsed/Refractory CLL: Ibrutinib Plus Venetoclax

February 14th 2022

Considerations for treating patients with relapsed/refractory chronic lymphocytic leukemia with the combination of ibrutinib and venetoclax.

Fixed-Duration Therapy in Frontline CLL: Venetoclax Plus Obinutuzumab

February 14th 2022

The rationale for investigating the fixed-duration, all-oral combination regimen of venetoclax with obinutuzumab as treatment for chronic lymphocytic leukemia.

Fixed-Duration Therapy in Frontline CLL: Ibrutinib Plus Venetoclax

February 7th 2022

Key takeaways from the CAPTIVATE and GLOW trials of ibrutinib plus venetoclax as fixed-duration frontline therapy for chronic lymphocytic leukemia.

Frontline Therapy for CLL: Treatment Selection Based on Patient and Treatment Factors

February 7th 2022

Variables that impact which Bruton tyrosine kinase inhibitor is most appropriate as frontline therapy for patients with newly diagnosed chronic lymphocytic leukemia and the role of patient and disease factors in treatment selection.

Implications for Zanubrutinib as CLL Treatment

January 31st 2022

An overview of safety and efficacy data for a third-generation Bruton tyrosine kinase inhibitor, zanubrutinib, as treatment for patients with chronic lymphocytic leukemia.

Acalabrutinib as Frontline Therapy for CLL

January 31st 2022

Features that distinguish acalabrutinib, a second-generation Bruton tyrosine kinase inhibitor, from ibrutinib as frontline therapy for patients with chronic lymphocytic leukemia.

Ibrutinib Therapy for CLL: Long-Term Data

January 24th 2022

Reactions to longer-term follow-up data presented in 2021 on the use of ibrutinib as frontline treatment for patients with chronic lymphocytic leukemia.

BTK Inhibitors as Frontline Therapy for CLL

January 24th 2022

The rationale for using Bruton tyrosine kinase inhibitors, such as the first-generation option, ibrutinib, as first-line treatment for chronic lymphocytic leukemia.

Dr. Wierda on Future Research Directions With MRD in CLL

October 25th 2021

William G. Wierda, MD, PhD, discusses future research directions with minimal residual disease testing in patients with chronic lymphocytic leukemia.

Dr. Wierda on Ongoing Research Efforts Examining Fixed-Duration Strategies in CLL

October 21st 2021

William G. Wierda, MD, PhD, discusses efforts to examine fixed-duration treatment strategies in patients with chronic lymphocytic leukemia.

Dr. Wierda on the Safety and Efficacy Results of the TRANSCEND CLL 004 Trial in CLL

September 23rd 2021

William G. Wierda, MD, PhD, discusses the safety and efficacy results of the phase 1/2 TRANSCEND CLL 004 trial in chronic lymphocytic leukemia.